Sage Journals: Discover world-class research

Abstract

Mucormycosis is a rare, life-threatening opportunistic infection primarily affecting immunocompromised patients. The available literature on Rhizomucor pusillus (R pusillus) infections of the central nervous system (CNS) in children is very limited. We present the case of an immunocompromised adolescent with intracranial mucormycosis due to R pusillus manifesting with stroke-like symptoms. This case highlights this rare condition's diagnostic complexity and management challenges. We include a review of the available literature on pediatric R pusillus CNS infections to increase awareness among health care providers.

Keywords

CNS infections Isolated intracranial mucormycosis

Mucormycosis is a life-threatening infection caused by fungi in the order Mucorales, which includes several genera of pathogenic fungi, such as Rhizopus, Mucor, and Rhizomucor.^1,2 CNS mucormycosis is rare but with increasing incidence. These fungi are primarily opportunistic pathogens, typically affecting immunocompromised individuals, particularly those with uncontrolled diabetes mellitus, malignancies, hematopoietic or solid-organ transplantation, and, most recently, COVID-19.^2-4 It can be particularly aggressive, with high morbidity and mortality rates ranging up to 60%, even with timely diagnosis and treatment.³ Rhizomucor species account for up to 6% of mucormycosis, causing predominantly pulmonary and disseminated infections and less commonly cutaneous, rhino-orbito-cerebral, and gastrointestinal infections.^1,2,4

Although its occurrence in the CNS is rare, when present, it can lead to infarction, necrosis, and hemorrhage because of its angio-invasive nature. Such cases are exceedingly uncommon in pediatric patients, and limited literature is available to guide clinical decision making.

This case report describes an unusual presentation of a likely isolated intracranial Rhizomucor pusillus infection in an adolescent with T-cell acute lymphoblastic leukemia, initially diagnosed as an arterial ischemic stroke. We also review the literature on pediatric rhizomucor infection and present an overview of the pathophysiology, diagnosis, and treatment options available.

Case Report

A 16-year-old right-handed female adolescent with T-cell acute lymphoblastic leukemia in induction therapy presented to the clinic with scleral icterus, conjugated hyperbilirubinemia, and elevated aspartate transaminase, alanine transaminase, and International Normalized Ratio (INR). During the visit, she experienced weakness and a minor fall, leading to hospitalization for further evaluation and management of acute liver failure with coagulopathy.

Her most recent chemotherapeutic plan included dexamethasone, daunorubicin, and vincristine administered 1 week before admission, with earlier courses including pegasparginase and methotrexate. She was also receiving prophylactic trimethoprim-sulfamethoxazole, micafungin, and norethindrone.

On admission, she reported a 1-week history of bilateral lower extremity weakness and numbness in her toes. Four days into hospitalization, she developed acute numbness in her left fingertips, which rapidly progressed to involve her entire left hand, causing difficulty holding objects. Intermittent left-sided abdominal, back, and hip pain were also reported. These new neurologic symptoms prompted the activation of an acute stroke alert.

Physical examination revealed an afebrile, cachectic adolescent with mild scleral icterus. Neurologic examination showed that she was alert and oriented, with intact speech and language. Mild left nasolabial fold flattening was noted, along with left-sided pronator drift and an inability to shrug her left shoulder. The rest of the cranial nerve examination was unremarkable. Sensorimotor examination revealed weakness on left distal upper extremity flexion and extension and bilateral hip flexion. Sensation to light touch was reduced distally in the left upper extremity and bilateral lower extremities. Vibration sense was decreased in the bilateral feet extending to the ankle on the right and the knee on the left. Coordination and deep tendon reflexes were intact. The National Institutes of Health Stroke Scale (NIHSS) was 9 for facial palsy, extremity weakness, and sensation deficit.

Initial brain magnetic resonance imaging (MRI; Figure 1a) showed focal diffusion restriction in the right peri-rolandic region and right centrum semiovale, involving the precentral more than the postcentral gyrus, suggesting acute ischemia. No evidence of stenosis or occlusion was seen on arterial and venous vessel imaging of the head and neck. Spine MRI was notable for lumbar disc degeneration but was otherwise unremarkable. Furthermore, additional blood workup showed no significant abnormalities (Table 1). COVID-19 test was negative.

Figure 1.
Sequential MRI changes over time. (a) Day 0: stroke MRI axial DWI showing restricted diffusion in the right perirolandic region and centrum semiovale, suggestive of acute ischemia at the time of presentation. (b) Day 13: axial FLAIR showing a small new collection at the prior suspected ischemia site with prominent surrounding vasogenic edema, concerning for hemorrhagic conversion. (c) Day 18: axial FLAIR demonstrating further increase in mass effect, vasogenic edema, and collection size, with a subtle developing rim of T2-weighted and FLAIR hypointensity. (d) Day 21: axial T1-weighted postcontrast showing enlarged lesion with thick rim enhancement, involving the cortex and subcortical white matter with central necrosis, vasogenic edema, mass effect with mild right-to-left midline shift. (e) Day 196: axial T1-weighted postcontrast and (f) axial T2-weighted showing postoperative contraction of the lesion with improvement in vasogenic edema and mass effect. DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; MRI, magnetic resonance imaging.

Table 1.
Relevant Clinical Test Results and Their Clinical Significance for the Patient's Evaluation.

Test Result Notes

CSF

Color Colorless Common for normal CSF

Clarity Clear Indicates absence of infection or bleeding

Xanthochromia Absent Indicates no old blood present

WBC 0 Indicates no infection or inflammation

RBC 4 Low count, nonspecific

Cytology Negative for malignancy

Brain core needle biopsy

Intraoperative assessment Purulent thick yellow material and abnormal tissue appearance Suggests infection or inflammation

Cultures Negative anaerobic bacteria, mycobacteria, yeast, and filamentous fungus. Many WBC

Universal PCR Moraxella porci Ubiquitous organism

Karius test Acinetobacter haemolyticus at low levels Ubiquitous organism

Tissue examination Necrotic tissue viable parenchyma with abundant macrophages Indicates ongoing inflammation and immune response

Open brain biopsy

Intraoperative assessment Thick-walled lesion containing purulent material Indicates the presence of an infection or abscess

Cultures Negative anaerobic bacteria, mycobacteria, yeast, and filamentous fungus. Many WBC

Universal PCR Positive for Rhizomucor pusillus. Negative for bacteria and mycobacteria

Tissue examination Abscess with central necrosis, granulation tissue, and fibrous capsule Shows advanced infection response with tissue remodeling

Abbreviations: CSF, cerebrospinal fluid; PCR, polymerase chain reaction; RBC, red blood cells; WBC, white blood cell.

At this stage, the acute ischemia noted on imaging was attributed to the hypercoagulable state associated with asparaginase and coagulopathy in the setting of liver failure and malignancy. Her lower extremity sensorimotor symptoms were attributed to vincristine-induced peripheral neuropathy.

Over the next 2 days, her weakness progressed to involve the face and more prominent weakness of the left upper extremity. A repeat brain MRI showed an enlarged region of diffusion restriction with new associated petechial hemorrhages. Given her persistent thrombocytopenia and risk of hemorrhagic conversion, anticoagulation was deferred, and the patient was started on aspirin. Despite physiotherapy, the patient's neurologic status continued to decline, with worsening hip flexor weakness. This deterioration was attributed to her critical illness and steroid use.

On day 13 of hospitalization, she developed stuttering episodes and complete paresis of her entire left upper extremity. Brain MRI (Figure 1b) suggested hemorrhagic conversion within the previous area of diffusion restriction and extensive vasogenic edema, despite improved thrombocytopenia and coagulopathy. Interval CTA was stable. Electroencephalogram (EEG) was without epileptiform activity and accompanying lab work was unremarkable.

By day 18, the patient developed worsening right-sided headaches, but remained afebrile and hemodynamically stable. A repeat brain MRI (Figure 1c) demonstrated increased vasogenic edema surrounding the hemorrhage, with associated midline shift, prompting the initiation of dexamethasone.

On day 21, contrast-enhanced MRI (Figure 1d) revealed a large ring-enhancing lesion with progressive surrounding edema at the location of initial restricted diffusion. Notably, laboratory results, including CSF studies, did not indicate an active infectious process.

A diagnostic brain biopsy was performed, and necrosis was observed on tissue examination. Routine tissue cultures were negative for microorganisms. Universal polymerase chain reaction (PCR) for bacteria, fungi, and mycobacteria was positive for Moraxella porci. Plasma metagenomic next-generation sequencing for pathogen identification identified Acinetobacter haemolyticus at low levels. Antimicrobials were not initiated because these organisms were considered highly unlikely to be the cause of her brain lesion. Although her left upper extremity weakness continued, she could walk again with assistance, and this was seen as an improvement off antibiotics.

On day 35, the patient had a 2-minute generalized tonic-clonic seizure that resolved spontaneously. Imaging revealed an enlarged lesion, prompting empirical initiation of metronidazole and ceftriaxone. After 2 weeks of antibiotic therapy, there was no reduction in lesion size on imaging.

On day 53, she underwent an open brain biopsy. Multiple samples were taken, including fluid from the lesion and tissue from the leading edge of the lesion. Routine cultures and stains were again negative for microorganisms. PCR for bacteria and mycobacteria remained negative. Tissue examination showed nonspecific necrosis and granulation tissue. On day 61, universal fungal PCR identified R pusillus. Antifungal therapy was initiated with liposomal amphotericin B and posaconazole.

Initial MRI showed no evidence of sinus disease. However, at 3 weeks post-stroke, there was moderate mucosal thickening in the right frontal and right maxillary sinuses, with mild thickening in the bilateral ethmoid sinuses. These changes resolved spontaneously before antifungal treatment was initiated (please see supplementary material). The patient's clinical course was complicated by pancreatitis, which improved within days and was deemed unlikely infectious in etiology or related to the antifungal therapy. Chest computed tomography (CT) about 2 weeks into antifungal therapy showed left lingular consolidation, which raised concerns for fungal involvement and abnormal contrast enhancement around the central venous catheter, suggesting a possible thrombus. However, further investigations, including pathology, culture, and PCR of bronchoalveolar lavage samples, and echocardiogram did not suggest fungal infection or thrombus. This consolidation was not present on the chest radiograph 1 month prior to the stroke, and was almost completely resolved when CT chest was repeated 3 weeks later.

Liposomal amphotericin B was continued for 45 days, and posaconazole is being continued indefinitely at the time of this report. The patient continued to experience headaches, but her neurologic examination improved. Follow-up MRIs after day 80 (Figure 1e and f), demonstrated a collapsing abscess and reduced edema, along with new cystic changes in the right postcentral gyrus consistent with fungal disease.

Two years after the initial presentation, while in remission from acute lymphoblastic leukemia, the patient presented with a seizure and was found to have subtherapeutic levetiracetam and posaconazole levels. In the interim, she had developed steroid-induced diabetes mellitus. She subsequently underwent craniotomy for incision and drainage of 2 small adjacent abscesses, located slightly anterior to the original site. Pathology was consistent with an organizing abscess, and was negative for malignancy or fungal elements. Gram stain, cultures, and tissue PCR for bacteria, fungus, and mycobacteria remained negative. This was presumed to be a recurrence of her initial R pusillus infection related to her poorly controlled diabetes mellitus and subtherapeutic posaconazole levels. She received 6 additional weeks of amphotericin B and then continued long-term posaconazole therapy. Postsurgical MRI showed no residual abscess and decrease in surrounding edema.

Literature Review

Methods

A comprehensive literature search was conducted using the following electronic databases: PubMed, Embase, and CINAHL. The search covered all records from the database's inception to January 2024. The search strategy included keywords and Medical Subject Headings (MeSH) terms “rhizomucor pusillus” and “case report” or “case series.” No language or publication status restrictions were applied.

We included all studies in English or Spanish, cases of patients 18 years of age and younger who were diagnosed with intracranial R pusillus. We excluded conference abstracts and studies for which the full text was unavailable.

Two reviewers independently screened the titles and abstracts of all retrieved records. Full texts of potentially relevant articles were then assessed for eligibility based on the inclusion and exclusion criteria. Disagreements between reviewers were resolved through discussion.

The PRISMA flow diagram illustrates the study selection process (please see supplementary material for the selection process). Four studies met the inclusion criteria and were included in the systematic review.

Data were extracted using Excel, including information on study characteristics (author and year), participant demographics, diagnosis, intervention details, and clinical outcomes.

Results

Four articles met our inclusion criteria for our literature review, with 4 cases of intracranial R pusillus involving systemic pathology in pediatric patients (Table 2).^5-8 Cases had disseminated disease, and we did not find any cases of isolated intracranial R pusillus in the pediatric literature. The identified cases presented with varied symptoms, including altered mental status, fever, hemiparesis, and seizures. Three of the 4 cases involved immunocompromised states because of genetic immunodeficiency, hematologic malignancies, chemotherapy, or immunosuppressive therapy. The fourth likely developed functional immunosuppression resulting from trauma, surgery, and corticosteroid use. Despite aggressive treatments, including antifungals and broad-spectrum antibiotics, the patients experienced significant morbidity, with mortality in 2 of the 4 cases due to rapid disease progression and multiorgan involvement. Diagnostics used across the cases included CT and MRI scans and blood cultures. In one of the surviving cases, decompressive craniectomy was performed. In those who survived, liposomal amphotericin B was used.

Table 2.
Literature Search Results: 4 Cases of Intracranial Rhizomucor pusillus in Pediatric Patients.

Authors Age, gender Primary diagnosis Reason for admission Immune status Symptoms Workup Initial impression Identification Infection source/ spread Location in brain Treatment Prognosis

Shigemura et al, 2014 3 y, male p67 phox- deficient chronic granulomatous disease Hematopoietic stem cell transplantation Immunocompromised, details unspecified Hemiparesis, fever, cough, abdominal pain, unconsciousness; 32 days after transplant Galactomannan antigen and β-d-glucan negative, elevated CRP Engraftment syndrome, unspecified PCR assay, histopathology of necropsy of both kidneys Unknown/ disseminated Bilateral frontal and left parietal lobes 8 d before HSCT: micafungin at 5 mg/kg was infused dailyDay 13: methylprednisolone Died of multiple organ failure 49 days after HSCT

Pozo-Laderas et al, 2015 17 y, male Craniofacial trauma from a motorcycle accident 11 days prior to presentation with reconstruction surgery day 6 Generalized tonic-clonic seizure Immunocompetent Altered mental status and fever, 9 d posttrauma and 2 days before seizure. Later developed necrotic lesions on nose CSF leukocytosis, positive galactomannan, head CT negative, aspergillosis Posttraumatic meningoencephalitis Biopsy of gut, sinuses Unknown/ disseminated Right frontotemporal lobes Day 14-26: Amoxicillin- clavulanic acid, meropenem, linezolid, voriconazole>Day 26: liposomal amphotericin 6 mg/kg/d for 7 weeks Progressed to uncal herniation, required decompressive craniectomy. Was comatosed for 2 months, eventually discharged alert with left hemiparesis. No recurrence after 2 years

Schober et al, 2021 7 y, male Relapse of pre-B-ALL Treatment with blinatumomab after second relapse Immunocompromised; WBC 940/μL with 50/μL neutrophils, Flank pain, somnolence, starting day 6 after blinatumomab Multiple cerebral hemorrhages, pancytopenia, elevated CRP, multiple thrombi in heart Morphine overdose, blinatumomab toxicity, thromboembolic stroke Autopsy, via PCR Unknown/ disseminated Multifocal cerebral lesion septic embolic infarctions and bleeding Started before symptom onset. Antibiotic regimen intensified (meropenem, teicoplanin, gentamicin), caspofungin continued Increased intracranial pressure, herniation, Approximately 24 hours from neurologic symptom onset to death

Shi et al, 2022 18 y, male Philadelphia-like acute B precursor lymphoblastic leukemia Hematopoietic malignancy, starting induction chemotherapy Immunocompromised; WBC: 200-360/μL with 97% lymphatic blasts Toothache, sore throat, abdominal pain, fever 3 days post agranulocytosis Elevated CRP, negative blood cultures, galactomannan and β-d-glucan negative, possible lung infection Malignancy course, unspecified fungal disease Cell-free DNA sequencing, silver staining and qPCR on biopsy tissue Possible neck skin/ disseminated Bilateral, likely frontal and left parietal lobes Day 1-14: meropenem caspofunginDay 15-21: voriconazoleDay 21-35; amphotericin 0.1- 3 mg/kg/day>Day 35: amphotericin and posaconazole Recovered, amphotericin and posaconazole continued for 6 months

Abbreviations: CRP, C-reactive protein; CSF, cerebrospinal fluid; CT, computed tomography; HSCT, hematopoietic stem cell transplantation; PCR, polymerase chain reaction; Pre-B ALL, pre-B acute lymphoblastic leukemia; WBC, white blood cell.

Discussion

Summary

We describe a case of likely isolated intracranial R pusillus infection. Our patient presented with focal neurologic deficits, with features more suggestive of arterial ischemic stroke and absent signs and symptoms of intracranial infection. The disease progression was slow. The hemorrhagic component of the lesion was unusual for an ischemic stroke because it was noted 2 weeks after her initial symptoms. Moreover, the degree of vasogenic edema appeared out of proportion compared to the size of the hemorrhage. Her initial workup revealed low levels of A haemolyticus on plasma metagenomic next-generation sequencing and M porci on tissue bacterial PCR. The former is not known to cause intracranial abscesses, and the latter is not a known human pathogen, and neither organism grew from tissue cultures. Additionally, the patient was not neutropenic for at least 3 weeks before the initial presentation. Although needle biopsy was unrevealing, universal PCR tissue from an open biopsy detected R pusillus. The fungus did not grow on culture, clinical examinations showed no evidence of sinus involvement, and there was no evidence of its spreading from adjacent structures on repeated imaging, supporting that the infection did not arise from contiguous spread. Incidentally identified pulmonary consolidation presented a possible source of noncontiguous spread, but this is considered unlikely as chest imaging before her stroke did not show evidence of infection nor did she have respiratory symptoms or fever in this period to suggest infection, and bronchoalveolar lavage showed no evidence of pulmonary fungal infection. Although the overall clinical course was atypical for such an infection, treatment was started based on a risk-benefit evaluation and resulted in improvement of neurologic symptoms.

Mucormycosis-associated intracranial infection has been reported in adults and children. Notably, we did not find a case of isolated intracranial R pusillus mucormycosis in pediatric literature in our systematic review. Cases have been reported in immunocompromised adults.^9-11 Farid et al¹¹ reported a case of isolated R pusillus, an immunocompromised adult with chronic lymphocytic leukemia and a history of stem cell transplant, presenting with a generalized tonic-clonic seizure and expressive aphasia. The patient was afebrile, and otherwise, his examination was noncontributory. The lesion was resected. R pusillus was identified on histopathology and RNA sequencing, for which the patient was treated with liposomal amphotericin B, followed by posaconazole with a good response.

Pathophysiology

R pusillus is thermophilic, allowing growth in febrile patients.^1,12 This fungus is ubiquitous in the environment and can be airborne both outdoors and inside hospitals.^1,12 Rhizomucor is transmitted through environmental exposure to fungal spores by inhalation, direct contact, or rarely ingestion.¹²

Cerebral mucormycosis is commonly rhinosinogenic in origin, spreading by direct tissue invasion from adjacent infected tissues, usually the paranasal sinuses. This is particularly prevalent in diabetic patients, especially in the setting of diabetic ketoacidosis. Less often, infection occurs by hematogenous spread, typically in patients with hematological malignancies or recipients of stem cell transplants. Mucormycosis usually originates in the maxillary sinuses then spreads directly into adjacent tissue, including the periorbital tissues and cavernous sinus, which can cause cavernous sinus thrombosis. With perineural invasion, the fungus can extend into the brain parenchyma. The fungus in the sphenoid sinuses can spread to the cavernous sinus or infiltrate the carotid artery into the frontal and parietal lobes. Less likely infection can extend to the sagittal sinus, epidural and subdural spaces, and meninges.^13,14 Orbital infections are also seen.¹⁵ Isolated intracranial infections represent a less frequent but distinct category and are seen with intravenous drug abuse.^4,13

Rhizomucor virulence is associated with angioinvasion, leading to blood vessel occlusion and tissue ischemia, infarction, and necrosis. The hyphal growth in blood vessel lumens damages the endothelium and forms fungal emboli, causing occlusion and infarction. The fungus can also extravasate to the brain parenchyma, forming an abscess and predisposing to strokelike symptoms.¹⁰ The vascular complications, tissue inflammation, necrosis, and continued hyphal invasion manifest as headaches, sensory and motor deficits, cognitive disturbance, and seizures. Infection may also lead to coma and death. This hypoxic necrotic environment may impair immune cells’ access to the infection.¹³ Challenges to hemostasis, notably disease-related factors such as elevated serum sodium chloride levels, hyperglycemia, and hyperferremia, create a conducive environment that facilitates fungal invasion and further compromises the immune response.^13,16

Diagnosis

The diagnosis of intracranial mucormycosis is challenging, particularly in cases with atypical presentations like our patient. Signs and symptoms can be nonspecific, including headache, focal neurologic deficits, seizures, and altered mental status with or without signs of infection, occurring in both immunocompromised and even immunocompetent individuals.^5-11 Cases of strokes secondary to CNS fungal infections are reported with a negative CSF profile. These commonly involved anterior circulation strokes and hemorrhagic conversion have been reported.¹⁷

In our patient, CSF studies did not indicate CNS infection. Although pleocytosis in CSF is a common finding in CNS fungal infections, isolated abscesses, including fungal balls, are poorly evaluated with CSF analysis, particularly in the absence of leptomeningeal involvement.¹⁸ Mucorales do not release 1,3-beta-d-glucan or galactomannan, and currently no serum biomarkers are known to be helpful in the diagnosis of mucormycosis. Definitive diagnosis generally relies on tissue biopsy or abscess drainage with histopathology and culture.¹⁹ Culture can be negative because of fragility of hyphae in sample processing. Histopathology showing broad-based pauci-septate or aseptate hyphae with right-angle branching, especially when angioinvasion is present, is strongly suggestive of mucormycosis in a compatible clinical context. However, histopathology can be falsely negative, because of the extensive necrosis and thrombosis often present,¹⁹ as seen in our patient. PCR methods have emerged and show promise for establishing the diagnosis when culture and histopathology are inadequate, and even serum testing (metagenomic next-generation sequencing) may be useful establishing the diagnosis without invasive testing.^19,20

MRI may show a lesion with a T1-hyperintense rim with peripheral contrast enhancement and a T1-hypointense core in the fungal abscess. The abscess wall and projections show restricted diffusion on DWI with core sparing. Often, more than 1 abscess is seen.²¹ Certain spectroscopic profiles on MRS can help support diagnoses of fungal abscesses, such as elevated amino acids, lactate, and lipids, with decreased N-acetyl-aspartate, choline, and creatine.²²

Our patient's initial brain MRI demonstrated restricted diffusion in a nonvascular distribution without an associated T1/T2 abnormal signal or mass effect, which is suspicious for ischemic stroke. Vascular imaging was not suggestive of vasculopathy, occlusion, or stenoses. We observed persistent restricted diffusion, which is atypical for a stroke, as the ADC signal typically trends toward facilitated diffusion within a week. Second, hemorrhagic conversion occurred 2 weeks after the initial presentation, which is delayed compared with the expected time frame of within the first few days. Third, the mass effect and vasogenic edema significantly increased over time, contrary to the typical expectation of a gradual decrease in these parameters following a stroke.^23,24 Follow-up MRI without contrast (Figure 1b) showed the development of a collection, later with increasing mass effect and vasogenic edema (Figure 1c), which was further characterized in a subsequent brain MRI with contrast on day 21, demonstrating a thick layer of peripheral enhancement, surrounding vasogenic edema and trace peripheral rim of susceptibility artifact (Figure 1d). There was no evidence of interval rebleeding or evolution of blood products. The smooth peripheral rim was more suggestive of a developing abscess capsule. The imaging findings over time could be summarized as an initial focus of microvascular injury and ischemia, eventually developing a cerebral abscess. Posttreatment imaging showed a further thickened, collapsed abscess capsule (Figure 1e and f) with postprocedure changes and no definite residual purulent material. Of note, the initial MRI did not demonstrate sinus involvement. However, at the time of hemorrhagic conversion, there was opacification of the paranasal sinuses, which varied in degree over time and resolved completely before the initiation of antifungal therapy.

Treatment

Amphotericin B is the drug of choice for initial management of mucormycosis, usually as a liposomal formulation. Amphotericin concentrations in CSF tend to be low as it does not readily cross the blood-brain barrier, and fungal vascular occlusion may inhibit the drug from reaching the target tissue. However, some animal models suggest it may have good brain tissue penetration when tissue is inflamed. The antifungal azoles posaconazole and isavuconazole generally retain in vitro activity against the mucorales and are commonly used as salvage or step-down therapy, or in combination with amphotericin B, but this practice has not been adequately investigated. Treatment duration is case-dependent and usually lasts months, and depending on the patient's immune status, may be continued indefinitely to prevent relapse of infection, as seen in our patient. Medical treatment is usually combined with surgical debridement, which has been shown to improve survival.^10,13,25

Conclusion

R pusillus mucormycosis of the CNS is a rare, often fatal opportunistic infection. Isolated intracranial mucormycosis is especially rare. To our knowledge, this is the first reported case of likely isolated intracranial R pusillus infection in pediatrics, offering valuable insights into the presentation and management.

The case underscores the potential for intracranial mucormycosis to mimic stroke, without clear signs of infection, in an immunocompromised adolescent, emphasizing the need for clinicians to maintain a high index of suspicion for fungal infections even when initial presentations suggest other pathologies. The diagnostic challenges highlighted the critical role of serial imaging and advanced molecular techniques like PCR in identifying rare pathogens, particularly when conventional methods prove inconclusive.

Despite the delayed diagnosis, our patient's improvement with prolonged antifungal therapy demonstrates the potential for favorable outcomes with aggressive and sustained treatment, even in cases of advanced infection. This finding is particularly significant given the typically poor prognosis associated with intracranial mucormycosis.

We review 4 pediatric cases of intracranial R pusillus, all presenting with severe systemic pathology and resulting in significant morbidity and mortality. The study has several limitations. The rarity of intracranial mucormycosis in pediatric patients limits the generalizability of the findings. Additionally, the heterogeneity of cases, including variability in patient demographics, underlying conditions, and treatment regimens, poses challenges in drawing standardized conclusions.

Future research efforts should focus on developing more sensitive and specific diagnostic tools for early detection of fungal CNS infections, optimizing antifungal treatment regimens, and investigating long-term outcomes in survivors. Additionally, exploring preventive strategies for high-risk patients could prove valuable in reducing the incidence of these life-threatening infections.

Supplemental Material

sj-docx-1-jcn-10.1177_08830738251334939 - Supplemental material for Intracranial Rhizomucor Pusillus Mucormycosis in an Adolescent Triggering a Stroke Alert: A Case Report and a Systematic Review of Pediatric Cases

Supplemental material, sj-docx-1-jcn-10.1177_08830738251334939 for Intracranial Rhizomucor Pusillus Mucormycosis in an Adolescent Triggering a Stroke Alert: A Case Report and a Systematic Review of Pediatric Cases by Rima El Atrache, Melissa Mizerik, Joaquin Francisco Ruiz Lopez, Eric Engstrom, Karla Patricia Salazar, Mikael C. Guzman-Karlsson, Daniel Davila-Williams, Sonali Sen, Kristen S. Fisher and Jennifer C. Erklauer in Journal of Child Neurology

Test	Result	Notes
CSF
Color	Colorless	Common for normal CSF
Clarity	Clear	Indicates absence of infection or bleeding
Xanthochromia	Absent	Indicates no old blood present
WBC	0	Indicates no infection or inflammation
RBC	4	Low count, nonspecific
Cytology	Negative for malignancy
Brain core needle biopsy
Intraoperative assessment	Purulent thick yellow material and abnormal tissue appearance	Suggests infection or inflammation
Cultures	Negative anaerobic bacteria, mycobacteria, yeast, and filamentous fungus. Many WBC
Universal PCR	Moraxella porci	Ubiquitous organism
Karius test	Acinetobacter haemolyticus at low levels	Ubiquitous organism
Tissue examination	Necrotic tissue viable parenchyma with abundant macrophages	Indicates ongoing inflammation and immune response
Open brain biopsy
Intraoperative assessment	Thick-walled lesion containing purulent material	Indicates the presence of an infection or abscess
Cultures	Negative anaerobic bacteria, mycobacteria, yeast, and filamentous fungus. Many WBC
Universal PCR	Positive for Rhizomucor pusillus. Negative for bacteria and mycobacteria
Tissue examination	Abscess with central necrosis, granulation tissue, and fibrous capsule	Shows advanced infection response with tissue remodeling

Authors	Age, gender	Primary diagnosis	Reason for admission	Immune status	Symptoms	Workup	Initial impression	Identification	Infection source/ spread	Location in brain	Treatment	Prognosis
Shigemura et al, 2014	3 y, male	p67 phox- deficient chronic granulomatous disease	Hematopoietic stem cell transplantation	Immunocompromised, details unspecified	Hemiparesis, fever, cough, abdominal pain, unconsciousness; 32 days after transplant	Galactomannan antigen and β-d-glucan negative, elevated CRP	Engraftment syndrome, unspecified	PCR assay, histopathology of necropsy of both kidneys	Unknown/ disseminated	Bilateral frontal and left parietal lobes	8 d before HSCT: micafungin at 5 mg/kg was infused dailyDay 13: methylprednisolone	Died of multiple organ failure 49 days after HSCT
Pozo-Laderas et al, 2015	17 y, male	Craniofacial trauma from a motorcycle accident 11 days prior to presentation with reconstruction surgery day 6	Generalized tonic-clonic seizure	Immunocompetent	Altered mental status and fever, 9 d posttrauma and 2 days before seizure. Later developed necrotic lesions on nose	CSF leukocytosis, positive galactomannan, head CT negative, aspergillosis	Posttraumatic meningoencephalitis	Biopsy of gut, sinuses	Unknown/ disseminated	Right frontotemporal lobes	Day 14-26: Amoxicillin- clavulanic acid, meropenem, linezolid, voriconazole>Day 26: liposomal amphotericin 6 mg/kg/d for 7 weeks	Progressed to uncal herniation, required decompressive craniectomy. Was comatosed for 2 months, eventually discharged alert with left hemiparesis. No recurrence after 2 years
Schober et al, 2021	7 y, male	Relapse of pre-B-ALL	Treatment with blinatumomab after second relapse	Immunocompromised; WBC 940/μL with 50/μL neutrophils,	Flank pain, somnolence, starting day 6 after blinatumomab	Multiple cerebral hemorrhages, pancytopenia, elevated CRP, multiple thrombi in heart	Morphine overdose, blinatumomab toxicity, thromboembolic stroke	Autopsy, via PCR	Unknown/ disseminated	Multifocal cerebral lesion septic embolic infarctions and bleeding	Started before symptom onset. Antibiotic regimen intensified (meropenem, teicoplanin, gentamicin), caspofungin continued	Increased intracranial pressure, herniation, Approximately 24 hours from neurologic symptom onset to death
Shi et al, 2022	18 y, male	Philadelphia-like acute B precursor lymphoblastic leukemia	Hematopoietic malignancy, starting induction chemotherapy	Immunocompromised; WBC: 200-360/μL with 97% lymphatic blasts	Toothache, sore throat, abdominal pain, fever 3 days post agranulocytosis	Elevated CRP, negative blood cultures, galactomannan and β-d-glucan negative, possible lung infection	Malignancy course, unspecified fungal disease	Cell-free DNA sequencing, silver staining and qPCR on biopsy tissue	Possible neck skin/ disseminated	Bilateral, likely frontal and left parietal lobes	Day 1-14: meropenem caspofunginDay 15-21: voriconazoleDay 21-35; amphotericin 0.1- 3 mg/kg/day>Day 35: amphotericin and posaconazole	Recovered, amphotericin and posaconazole continued for 6 months

Footnotes

Acknowledgments

We thank the intensive care, infectious disease, hematology and oncology, neurology, and neurosurgery teams, as well as the nurses and physical therapists at Texas Children's Hospital, who contributed to the patient's recovery.

Author Contributions

REA contributed to conception and design, EE and MGK contributed to design, REA, MM, JRL, EE, and KS contributed to acquisition, analysis, and interpretation, MGK contributed to interpretation, REA, JRL, EE, and MGK drafted manuscript, DDW, SS, KF, and JE contributed to analysis and interpretation. All authors critically revised manuscript, gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Consent to Participate and Publication

Written informed consent was obtained from the patient and legally authorized representative for anonymized patient information to be published in this article.

Data Availability

The case report and literature review do not contain any data sets or quantitative/qualitative data as it is a clinical case description.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical Approval

No ethical approval was required.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iDs

Eric Engstrom

Kristen S. Fisher

Mikael C. Guzman-Karlsson

Rima El Atrache

Supplemental Material

Supplemental material for this article is available online.

References

Walther

Wagner

Kurzai

. Updates on the taxonomy of Mucorales with an emphasis on clinically important taxa. Journal of Fungi. 2019;5(4):106. doi:https://doi.org/10.3390/jof5040106

Jeong

Keighley

Wolfe

, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34. doi:https://doi.org/10.1016/j.cmi.2018.07.011

Pham

Howard-Jones

Sparks

, et al. Epidemiology, modern diagnostics, and the management of Mucorales infections. Journal of Fungi. 2023;9(6):659. doi:https://doi.org/10.3390/jof9060659

Roden

Zaoutis

Buchanan

, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653. doi:https://doi.org/10.1086/432579

Shigemura

Nakazawa

Matsuda

, et al. Serial monitoring of Mucorales DNA load in serum samples of a patient with disseminated mucormycosis after allogeneic bone marrow transplantation. Int J Hematol. 2014;100(2):206-209. doi:https://doi.org/10.1007/s12185-014-1597-8

Pozo-Laderas

Pontes-Moreno

Robles-Arista

, et al. Infección fúngica invasiva mixta por Rhizomucor pusillus y Aspergillus niger en un paciente inmunocompetente. Rev Iberoam Micol. 2015;32(1):46-50. doi:https://doi.org/10.1016/j.riam.2013.03.002

Schober

Cabanillas Stanchi

Riecker

, et al. Fulminant Rhizomucor pusillus mucormycosis during anti-leukemic treatment with blinatumomab in a child: a case report and review of the literature. Med Mycol Case Rep. 2021;32:4-9. doi:https://doi.org/10.1016/j.mmcr.2020.12.002

Shi

Zhao

Yan

, et al. Aggressive disseminated Rhizomucor pusillus infection in a Ph-like acute lymphoblastic leukemia patient: early detection by cell-free DNA next-generation sequencing. J Infect Chemother. 2022;28(3):459-464. doi:https://doi.org/10.1016/j.jiac.2021.12.007

Saini

Mann

Singh

, et al. Isolated cerebral mucormycosis: a case discussion. IDCases. 2023;33:e01821. doi:https://doi.org/10.1016/j.idcr.2023.e01821

10.

Chen

Guo

. Isolated cerebral mucormycosis that looks like stroke and brain abscess: a case report and review of the literature. World J Clin Cases. 2023;11(7):1560-1568. doi:https://doi.org/10.12998/wjcc.v11.i7.1560

11.

Farid

AbuSaleh

Liesman

Sohail

. Isolated cerebral mucormycosis caused by Rhizomucor pusillus. BMJ Case Rep. 2017;2017:bcr2017221473. doi:https://doi.org/10.1136/bcr-2017-221473

12.

Ribes

Vanover-Sams

Baker

. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236-301. doi:https://doi.org/10.1128/CMR.13.2.236-301.2000

13.

Chikley

Ben-Ami

Kontoyiannis

. Mucormycosis of the central nervous system. J Fungi. 2019;5(3):59. doi:https://doi.org/10.3390/jof5030059

14.

Parida

. Imaging of fungal infections of the brain. In: Fungal Infections of the Central Nervous System. Springer International Publishing; 2019:353-365. doi:https://doi.org/10.1007/978-3-030-06088-6_28

15.

Diaz

del Palacio Hernanz

Larregla

Lopez

. Orbital phycomycosis. Ophthalmologica. 1981;182(3):165-170. doi:https://doi.org/10.1159/000309108

16.

Montaño

Voigt

. Host immune defense upon fungal infections with Mucorales: pathogen-immune cell interactions as drivers of inflammatory responses. J Fungi. 2020;6(3):173. doi:https://doi.org/10.3390/jof6030173

17.

George

Ramiro

Gomes

Newey

Bhimraj

. Central nervous system fungal infection-related stroke: a descriptive study of mold and yeast-associated ischemic stroke. J Stroke Cerebrovasc Dis. 2020;29(6):104759. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104759

18.

Huang

Wang

. Clinical characteristics and outcome of primary brain abscess: a retrospective analysis. BMC Infect Dis. 2021;21(1):1245. doi:https://doi.org/10.1186/s12879-021-06947-2

19.

Wattier

William

Steinbach

. Mucormycosis and entomophthoramycosis. In: Cherry

, Demmler-Harrison GJ, Kaplan SL, Steinbach W, Hotez PJ, eds. Feigin and Cherry’s Textbook of Pediatric Infectious Diseases. 8th ed. Elsevier; 2018:2094-2102.

20.

Millon

Scherer

Rocchi

Bellanger

. Molecular strategies to diagnose mucormycosis. J Fungi (Basel). 2019;5(1):24. doi:https://doi.org/10.3390/jof5010024

21.

Gavito-Higuera

Mullins

Ramos-Duran

Olivas Chacon

Hakim

Palacios

. Fungal infections of the central nervous system: a pictorial review. J Clin Imaging Sci. 2016;6:24. doi:https://doi.org/10.4103/2156-7514.184244

22.

Duong

Rudie

Mohan

. Neuroimaging patterns of intracranial infections. Neuroimaging Clin N Am. 2023;33(1):11-41. doi:https://doi.org/10.1016/j.nic.2022.07.001

23.

Hong

Kim

. Hemorrhagic transformation after ischemic stroke: mechanisms and management. Front Neurol. 2021;12:703258. doi:https://doi.org/10.3389/fneur.2021.703258

24.

Albers

. Diffusion-weighted MRI for evaluation of acute stroke. Neurology. 1998;51(3 suppl 3):S47-S49. doi:https://doi.org/10.1212/WNL.51.3_Suppl_3.S47

25.

Petraitis

Petraitiene

Valdez

, et al. Amphotericin B penetrates into the central nervous system through focal disruption of the blood-brain barrier in experimental hematogenous Candida meningoencephalitis. Antimicrob Agents Chemother. 2019;63(12):e01626-19. doi:https://doi.org/10.1128/AAC.01626-19

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.47 MB